Abstract:Abstract Background The endocannabinoid (eCB) system and the serotonin (5-HT) are both implicated in the severity of the depression. 5-HT is synthesized from the amino acid tryptophan (Trp), which is also a precursor for kynurenine (Kyn) whose production is increased at the expense of 5-HT in depressed patients. No clinical studies have investigated the crosstalk between the eCB system and the Trp/5-HT/Kyn pathways. Here, we hypothesized that the eCB system is associated with an enhanced Kyn production in relation to the severity of depressive symptoms. Methods Eighty-two subjects (51 patients with a diagnosis of depressive disorder (DSM-5) and 31 healthy volunteers), were assessed with the Montgomery-Åsberg Depression Rating Scale (MADRS), Beck Depression Scale, and Global Clinical Impression. Serum concentrations of eCBs ( N -arachidonoylethanolamine (AEA) and 2-arachidonoylglycerol (2-AG)); structurally related fatty acyl compounds 2-oleoylglycerol (2-OG), oleoylethanolamide (OEA), and palmitoylethanolamide (PEA); Trp, Kyn, Kyn/Trp ratio (an index of Trp degradation into Kyn) and 5-HT were also determined. Results Following a principal component analysis including the severity of depression, Kyn and the Kyn/Trp ratio appear to be directly associated with 2-AG, AEA, and PEA. Interestingly, these biomarkers also permitted to distinguish the population into two main clusters: one of individuals having mild/severe depressive symptoms and the other with an absence of depressive symptoms. Using parametric analysis, higher serum levels of 2-AG, Kyn, and the ratio Kyn/Trp and lower levels of Trp and 5-HT were found in individuals with mild/severe depressive symptoms than in those without depressive symptoms. While in asymptomatic people, PEA was directly associated to Trp, and OEA indirectly linked to 5-HT, in individuals with depressive symptoms, these correlations were lost, and instead, positive correlations between AEA and 2-AG, PEA and AEA, and PEA vs 2-AG and OEA concentrations were found. Conclusions Parametric and non-parametric analyses suggest a possible association between eCBs, tryptophan/kynurenine biomarkers, and severity of depression, confirming a likely interplay among inflammation, stress, and depression. The enhanced relationships among the biomarkers of the 2-AG and AEA pathways and related lipids seen in individuals with depressive symptoms, but not in asymptomatics, suggest an altered metabolism of the eCB system in depression.

Pro-Inflammatory Cytokines: Potential Links between the Endocannabinoid System and the Kynurenine Pathway in Depression

Dysfunction in endocannabinoids, palmitoylethanolamide, and degradation of tryptophan into kynurenine in individuals with depressive symptoms

Associations among peripheral and central kynurenine pathway metabolites and inflammation in depression

Inflammation and Nitro-oxidative Stress As Drivers of Endocannabinoid System Aberrations in Mood Disorders and Schizophrenia

Ketone Bodies and Inflammation Modulation: A Mini-Review on Ketogenic Diet's Potential Mechanisms in Mood Disorders

Immune Influencers in Action: Metabolites and Enzymes of the Tryptophan-Kynurenine Metabolic Pathway

The Cannabis-Induced Epigenetic Regulation of Genes Associated with Major Depressive Disorder

Ketamine’s effect on inflammation and kynurenine pathway in depression: A systematic review

Kynurenines Increase MRS Metabolites in Basal Ganglia and Decrease Resting-State Connectivity in Frontostriatal Reward Circuitry in Depression.

Kynurenines Increase MRS Metabolites in Basal Ganglia and Decrease Resting State Connectivity in Frontostriatal Reward Circuitry in Depression

Inflammation and Immune Regulation as Potential Drug Targets in Antidepressant Treatment

Inflammatory cytokines in depression: Neurobiological mechanisms and therapeutic implications

An overview of major depression disorder: The endocannabinoid system as a potential target for therapy

The kynurenine pathway: a finger in every pie

Neurobiological mechanisms in the kynurenine pathway and major depressive disorder

The endocannabinoidome in neuropsychiatry: Opportunities and potential risks

Endocannabinoid system: Role in depression, reward and pain control (Review).

Intertwined associations between oxidative and nitrosative stress and endocannabinoid system pathways: Relevance for neuropsychiatric disorders

The role and mechanism of tryptophan – kynurenine metabolic pathway in depression

Role of Inflammatory Mechanisms in Major Depressive Disorder: From Etiology to Potential Pharmacological Targets

Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression